MA42819A - Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae - Google Patents
Procédés pour le traitement d'infections virales à arenaviridae et coronaviridaeInfo
- Publication number
- MA42819A MA42819A MA042819A MA42819A MA42819A MA 42819 A MA42819 A MA 42819A MA 042819 A MA042819 A MA 042819A MA 42819 A MA42819 A MA 42819A MA 42819 A MA42819 A MA 42819A
- Authority
- MA
- Morocco
- Prior art keywords
- arenaviridae
- treatment
- methods
- viral infections
- coronaviridae viral
- Prior art date
Links
- 241000712892 Arenaviridae Species 0.000 title 1
- 241000711573 Coronaviridae Species 0.000 title 1
- 208000036142 Viral infection Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562219302P | 2015-09-16 | 2015-09-16 | |
US201562239696P | 2015-10-09 | 2015-10-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA42819A true MA42819A (fr) | 2018-07-25 |
Family
ID=56997582
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA042819A MA42819A (fr) | 2015-09-16 | 2016-09-16 | Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae |
MA052371A MA52371A (fr) | 2015-09-16 | 2016-09-16 | Méthodes de traitement d'infections dues aux coronaviridae |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052371A MA52371A (fr) | 2015-09-16 | 2016-09-16 | Méthodes de traitement d'infections dues aux coronaviridae |
Country Status (24)
Country | Link |
---|---|
US (5) | US10251904B2 (fr) |
EP (3) | EP3785717B1 (fr) |
JP (4) | JP6742403B2 (fr) |
KR (1) | KR20180050742A (fr) |
CN (5) | CN115844896A (fr) |
AU (3) | AU2016323604B2 (fr) |
BR (2) | BR122020020217B1 (fr) |
CA (1) | CA2998189C (fr) |
CY (1) | CY1125089T1 (fr) |
DK (2) | DK3785717T3 (fr) |
EA (1) | EA038141B1 (fr) |
ES (2) | ES2909419T3 (fr) |
HK (3) | HK1255732A1 (fr) |
HR (2) | HRP20220355T1 (fr) |
HU (2) | HUE057928T2 (fr) |
LT (2) | LT3349758T (fr) |
MA (2) | MA42819A (fr) |
MX (2) | MX2021005087A (fr) |
PL (2) | PL3349758T3 (fr) |
PT (2) | PT3785717T (fr) |
SG (2) | SG10202109869XA (fr) |
SI (2) | SI3785717T1 (fr) |
TW (1) | TW201733595A (fr) |
WO (1) | WO2017049060A1 (fr) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2480559T1 (sl) | 2009-09-21 | 2013-10-30 | Gilead Sciences, Inc. | Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov |
PT2595980E (pt) | 2010-07-22 | 2014-11-27 | Gilead Sciences Inc | Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae |
TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
DK3236972T3 (en) | 2014-12-26 | 2021-10-04 | Univ Emory | Antivirale N4-hydroxycytidin-derivativer |
CA2998189C (fr) * | 2015-09-16 | 2021-08-03 | Gilead Sciences, Inc. | Procedes pour le traitement d'infections virales a arenaviridae et coronaviridae |
US11617753B2 (en) | 2016-11-10 | 2023-04-04 | Oyagen, Inc. | Methods of treating and inhibiting Ebola virus infection |
CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
CN115403626A (zh) | 2017-05-01 | 2022-11-29 | 吉利德科学公司 | 新结晶形式 |
US10675296B2 (en) | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
KR20200098483A (ko) * | 2017-09-18 | 2020-08-20 | 얀센 바이오파마, 인크. | 치환된 뉴클레오시드, 뉴클레오티드 및 이들의 유사체 |
SG11202004403QA (en) | 2017-12-07 | 2020-06-29 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
CN110724174B (zh) * | 2019-09-10 | 2021-02-05 | 广州六顺生物科技股份有限公司 | 吡咯并三嗪类化合物、组合物及其应用 |
CN111265532A (zh) * | 2020-01-21 | 2020-06-12 | 中国人民解放军军事科学院军事医学研究院 | 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用 |
WO2021154687A1 (fr) | 2020-01-27 | 2021-08-05 | Gilead Sciences, Inc. | Procédés de traitement d'infections par sras cov-2 |
WO2021158248A1 (fr) | 2020-02-04 | 2021-08-12 | Oyagen, Inc. | Méthodes de traitement d'infections à coronavirus |
TW202322824A (zh) | 2020-02-18 | 2023-06-16 | 美商基利科學股份有限公司 | 抗病毒化合物 |
TWI775313B (zh) * | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
CN113292565B (zh) * | 2020-02-24 | 2023-01-31 | 浙江森科建设有限公司 | 核苷类化合物及其制备方法和应用 |
WO2021168930A1 (fr) * | 2020-02-25 | 2021-09-02 | 顾世海 | Comprimé de remdésivir et son procédé de préparation |
WO2021173713A1 (fr) * | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Composés hautement actifs contre la covid-19 |
CN111187269A (zh) * | 2020-02-27 | 2020-05-22 | 江苏阿尔法药业有限公司 | 一种瑞德西韦中间体的合成方法 |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
CN111205294B (zh) * | 2020-02-27 | 2021-10-01 | 江苏阿尔法药业股份有限公司 | 一种瑞德西韦中间体的制备方法 |
CN111233929B (zh) * | 2020-02-28 | 2023-02-28 | 成都阿奇生物医药科技有限公司 | 一种核苷类似物的氘代物及其制备方法和用途 |
CN113336758B (zh) * | 2020-03-03 | 2022-08-19 | 北京桦冠医药科技有限公司 | 化合物7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的一种新合成方法 |
US20230124467A1 (en) * | 2020-03-03 | 2023-04-20 | Mios Pharmaceuticals Limited | Compounds and methods for treating diseases and/or conditions caused by coronavirus |
CN111116656A (zh) * | 2020-03-04 | 2020-05-08 | 江苏福瑞康泰药业有限公司 | 一种瑞德西韦的制备方法 |
CN111269248A (zh) * | 2020-03-05 | 2020-06-12 | 江苏福瑞康泰药业有限公司 | 一种核苷氨基磷酸酯类药物母液回收的新方法 |
CN111233870A (zh) * | 2020-03-11 | 2020-06-05 | 中国科学技术大学 | 用于快速制备瑞德西韦药物中间体的方法 |
CN115298181A (zh) | 2020-03-12 | 2022-11-04 | 吉利德科学公司 | 制备1’-氰基核苷的方法 |
CN111393478B (zh) * | 2020-03-13 | 2023-05-26 | 深圳市宝安区新材料研究院 | 一种瑞德西韦的合成方法 |
WO2021186439A1 (fr) * | 2020-03-16 | 2021-09-23 | Bar-Ilan University | Molécules ciblant des protéines de coronavirus et leurs utilisations en tant que « cocktail » antiviral |
EP4132651A1 (fr) | 2020-04-06 | 2023-02-15 | Gilead Sciences, Inc. | Formulations d'inhalation d'analogues de carbanucléosides à substitution 1'-cyano |
CN116036031A (zh) * | 2020-04-07 | 2023-05-02 | 齐鲁制药有限公司 | 一种含有瑞德西韦的药物组合物 |
WO2021208910A1 (fr) * | 2020-04-13 | 2021-10-21 | 山东华铂凯盛生物科技有限公司 | Préparation de polymère pour le traitement d'infections virales, procédé de préparation et utilisation correspondants |
WO2021211757A1 (fr) * | 2020-04-14 | 2021-10-21 | Oyagen, Inc. | MÉTHODES DE TRAITEMENT D'INFECTIONS À ARÉNAVIRIDÉS<i /> |
CN111848679A (zh) * | 2020-04-17 | 2020-10-30 | 山东科巢生物制药有限公司 | 一种利用微通道反应技术合成瑞德西韦的方法 |
CN113521020B (zh) * | 2020-04-18 | 2023-05-02 | 齐鲁制药有限公司 | 一种含有水溶性酸的瑞德西韦固体剂型 |
CN112778310A (zh) * | 2020-04-20 | 2021-05-11 | 中国科学院上海药物研究所 | 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 |
CN111393243B (zh) * | 2020-04-22 | 2022-12-13 | 深圳市宝安区新材料研究院 | 一种磷手性核苷类药物的合成方法及该方法得到的药物 |
CN111440176B (zh) * | 2020-04-28 | 2022-04-26 | 江苏大学 | 金属配合物促进的瑞德西韦中间体的合成方法 |
CN111494349A (zh) * | 2020-04-30 | 2020-08-07 | 中国人民解放军空军军医大学 | 一种瑞德西韦口腔速溶膜及制备方法 |
CN113633617A (zh) * | 2020-05-11 | 2021-11-12 | 齐鲁制药有限公司 | 一种含有瑞德西韦的固体分散体、固体剂型及制备方法 |
WO2021234554A2 (fr) * | 2020-05-20 | 2021-11-25 | Lyrus Life Sciences Pvt Ltd | Nouvelle composition pour le traitement d'infections virales |
US20230277524A1 (en) | 2020-05-22 | 2023-09-07 | Trailhead Biosystems Inc. | Combination therapy for treatment of viral infections |
CA3179226A1 (fr) | 2020-05-29 | 2021-12-02 | Tomas Cihlar | Methodes de traitement par remdesivir |
US11020349B1 (en) * | 2020-07-14 | 2021-06-01 | Jubilant Generics Limited | Transmucosal dosage forms of remdesivir |
IN202011022634A (fr) | 2020-05-29 | 2020-10-09 | Jubilant Generics Limited | |
WO2021240543A1 (fr) * | 2020-05-29 | 2021-12-02 | Jubilant Generics Limited | Compositions pharmaceutiques transmuqueuses de médicaments antiviraux |
CN111620909B (zh) * | 2020-06-05 | 2022-12-02 | 广东中科药物研究有限公司 | 一种瑞德西韦的前体药物及其制备方法与应用 |
WO2021248229A1 (fr) * | 2020-06-11 | 2021-12-16 | Apotex Inc | Nouvelle forme cristalline de remdésivir |
US20210393663A1 (en) * | 2020-06-23 | 2021-12-23 | Cai Gu Huang | Pharmaceutical formulation containing active metabolites of remdesivir or its analog for inhalation |
CN115996928A (zh) * | 2020-06-24 | 2023-04-21 | 吉利德科学公司 | 1’-氰基核苷类似物及其用途 |
CN111732618A (zh) * | 2020-07-03 | 2020-10-02 | 镇江巨杰新材料技术研发中心(有限合伙) | 瑞德西韦关键片段的合成方法 |
WO2022008642A1 (fr) | 2020-07-08 | 2022-01-13 | Apeiron Biologics Ag | Traitement d'une infection par le sras-cov-2 avec une combinaison de cibles |
CN111875638A (zh) * | 2020-07-16 | 2020-11-03 | 江苏省原子医学研究所 | 一种瑞德西韦衍生物的制备方法、瑞德西韦衍生物及其应用 |
CN111961079A (zh) * | 2020-07-17 | 2020-11-20 | 南京正济医药研究有限公司 | 一种瑞德西韦有关物质及其制备方法和应用 |
WO2022020886A1 (fr) * | 2020-07-27 | 2022-02-03 | Microbio Pty Ltd | Procédé de détection de réplication virale |
PE20231983A1 (es) | 2020-08-27 | 2023-12-12 | Gilead Sciences Inc | Compuestos y metodos para el tratamiento de infecciones virales |
CN112358504A (zh) * | 2020-09-28 | 2021-02-12 | 南京正济医药研究有限公司 | 一种瑞德西韦有关物质及其制备方法和用途 |
CN112194680A (zh) * | 2020-09-29 | 2021-01-08 | 佛山科学技术学院 | 核苷酸氨基磷酸酯化合物、其药物组合物及其制备方法和应用 |
CN112194681A (zh) * | 2020-09-29 | 2021-01-08 | 佛山科学技术学院 | 核苷酸长链氨基磷酸酯化合物、其药物组合物及其制备方法和应用 |
US11612614B2 (en) * | 2020-10-20 | 2023-03-28 | Anzalp Pharmasolutions Pvt. Ltd. | Isomorphs of Remdesivir and methods for synthesis of same |
CN112300236A (zh) * | 2020-10-21 | 2021-02-02 | 佛山科学技术学院 | 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用 |
CN117777141A (zh) * | 2020-12-30 | 2024-03-29 | 南方科技大学 | 一种抗病毒感染的核苷类化合物及其用途 |
CN113754665B (zh) * | 2020-12-30 | 2022-08-19 | 南方科技大学 | 一种核苷类化合物的制备方法 |
US20220241300A1 (en) * | 2021-01-20 | 2022-08-04 | Regents Of The University Of Minnesota | Next generation remdesivir antivirals |
WO2022166581A1 (fr) * | 2021-02-07 | 2022-08-11 | 石家庄迪斯凯威医药科技有限公司 | Dérivé nucléotidique, composite pharmaceutique de celui-ci et son utilisation |
CN113105504A (zh) * | 2021-03-30 | 2021-07-13 | 澳门科技大学 | Remdesivir衍生物、其类似物及其制备方法与应用 |
CN117120444A (zh) | 2021-04-16 | 2023-11-24 | 吉利德科学公司 | 使用酰胺制备卡巴核苷的方法 |
CN115947758A (zh) * | 2021-10-07 | 2023-04-11 | 南京知和医药科技有限公司 | 一种核苷酸衍生物及其药物组合物和用途 |
CN114213366A (zh) * | 2022-01-17 | 2022-03-22 | 江西师范大学 | 一种氟代糖内酯合成方法 |
WO2023167944A1 (fr) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Composés et méthodes pour traiter des infections virales |
WO2023194840A1 (fr) | 2022-04-05 | 2023-10-12 | Unichem Laboratories Limited | Composés tricycliques substitués et leur utilisation dans la covid-19 |
US20240051962A1 (en) * | 2022-06-29 | 2024-02-15 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
US11655255B2 (en) | 2022-10-17 | 2023-05-23 | Sph No.1 Biochemical & Pharmaceutical Co., Ltd. | Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein |
Family Cites Families (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
CA2083386C (fr) | 1990-06-13 | 1999-02-16 | Arnold Glazier | Bioprecurseur phosphore |
EP0481214B1 (fr) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Pro-médicaments dérivés de phosphonates |
JPH1017629A (ja) | 1996-07-04 | 1998-01-20 | Kayaku Akzo Kk | ハードコート用樹脂組成物及びその硬化方法 |
US6887707B2 (en) | 1996-10-28 | 2005-05-03 | University Of Washington | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
KR20010041533A (ko) | 1998-03-03 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | (2e)-5-아미노-5-메틸헥스-2-엔오산n-메틸-n-((1r)-1-(n-메틸-n-((1r)-1-(메틸카르바모일)-2-페닐에틸)카르바모일)-2-(2-나프틸)에틸)아미드의신규한 염 형태 |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
US6475985B1 (en) | 1998-03-27 | 2002-11-05 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
EP1121361B1 (fr) | 1998-10-16 | 2007-08-29 | Merck Sharp & Dohme Limited | Derives pyrazolo-triazine utilises en tant que ligands des recepteurs gaba |
DE19912636A1 (de) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
MXPA01012444A (es) | 1999-06-03 | 2002-07-30 | Abbott Lab | Sintesis de oligonucleotido con acidos de lewis como activadores. |
AUPQ105499A0 (en) | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
US6656915B1 (en) | 1999-09-15 | 2003-12-02 | Biocryst Pharmaceuticals, Inc. | Inhibiting T-cell proliferation |
US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
EA200200778A1 (ru) | 2000-02-18 | 2003-06-26 | Шайре Байокем Инк. | СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С В ОРГАНИЗМЕ ХОЗЯИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ПРОТИВ ФЛАВИВИРУСА, СОЕДИНЕНИЕ ФОРМУЛЫ Ib - АКТИВНЫЙ АГЕНТ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С ИЛИ ФЛАВИВИРУСА (ВАРИАНТЫ) |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
EP1294735A2 (fr) | 2000-05-26 | 2003-03-26 | Novirio Pharmaceuticals Limited | Procedes et compositions de traitement des flavivirus et des pestivirus |
CZ304734B6 (cs) | 2000-07-21 | 2014-09-10 | Gilead Sciences, Inc. | Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
KR101201552B1 (ko) | 2000-10-18 | 2012-11-15 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
RS50236B (sr) | 2001-01-22 | 2009-07-15 | Merck & Co.Inc., | Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze |
DE10145223A1 (de) | 2001-09-13 | 2003-04-03 | Basf Ag | Verfahren zur Herstellung von meso-Zeaxanthin |
US20040006002A1 (en) | 2001-09-28 | 2004-01-08 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
AT410792B (de) | 2001-12-28 | 2003-07-25 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung |
AU2003213628A1 (en) | 2002-02-28 | 2003-09-16 | Biota, Inc. | Nucleoside 5'-monophosphate mimics and their prodrugs |
AU2003217863B9 (en) | 2002-02-28 | 2009-10-29 | Biota Scientific Management Pty Ltd | Nucleotide mimics and their prodrugs |
US20040138170A1 (en) | 2002-03-06 | 2004-07-15 | Montgomery John A. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
GB0210127D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
GB0210124D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
MXPA04010983A (es) | 2002-05-06 | 2005-02-14 | Genelabs Tech Inc | Derivados de nucleosidos para tratar infecciones por el virus de la hepatitis c. |
AU2003233667A1 (en) | 2002-05-23 | 2003-12-12 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
CN1849142A (zh) | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′-支链核苷和黄病毒突变 |
NZ542342A (en) | 2003-04-25 | 2009-05-31 | Gilead Sciences Inc | Antiviral phosphonate analogs |
WO2004112687A2 (fr) | 2003-06-26 | 2004-12-29 | Biotron Limited | Compositions et methodes antivirales |
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
DK1658302T3 (da) | 2003-07-25 | 2010-11-22 | Idenix Pharmaceuticals Inc | Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C |
BRPI0414019A (pt) | 2003-08-27 | 2006-10-24 | Biota Inc | nucleosìdios ou nucleotìdio tricìclicos como agentes terapêuticos |
EA011158B1 (ru) | 2004-03-16 | 2009-02-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения |
EP1758453B1 (fr) | 2004-06-15 | 2014-07-16 | Merck Sharp & Dohme Corp. | Analogues nucleosidiques de c-purine, servant d'inhibiteurs d'arn-polymerase virale arn-dependante |
WO2006002231A1 (fr) | 2004-06-22 | 2006-01-05 | Biocryst Pharmaceuticals, Inc. | Azanucleosides, leur preparation et leur utilisation comme inhibiteur des arn polymerases virales |
AU2005285045B2 (en) | 2004-09-14 | 2011-10-13 | Gilead Pharmasset Llc | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
CN101043893A (zh) | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA-依赖性RNA病毒感染的氟化吡咯并[2,3-d]嘧啶核苷 |
CA2584367A1 (fr) | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Nucleosides de pyrrolo[2,3-d]pyrimidine fluores destines au traitement d'infections ribovirales dependantes de l'arn |
JP5089395B2 (ja) | 2004-10-29 | 2012-12-05 | バイオクライスト ファーマシューティカルズ, インコーポレイテッド | 治療用フロピリミジンおよびチエノピリミジン |
US7687469B2 (en) | 2004-12-16 | 2010-03-30 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2006094347A1 (fr) | 2005-03-08 | 2006-09-14 | Biota Scientific Management Pty Ltd. | Nucleosides bicycliques et nucleotides servant d’agents therapeutiques |
EP2537520A1 (fr) | 2005-03-29 | 2012-12-26 | Biocryst Pharmaceuticals, Inc. | Thérapies hépatiques C |
WO2006116557A1 (fr) | 2005-04-25 | 2006-11-02 | Genelabs Technologies, Inc. | Composes nucleosides pour le traitement d’infections virales |
WO2006121820A1 (fr) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Promedicaments de phosphoramidate pour traitement d'infections virales |
WO2007027248A2 (fr) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | Analogues de nucleoside cyclique 3', 5' pour le traitement du virus de l'hepatite c (vhc) |
DK2826770T3 (en) | 2005-06-24 | 2019-01-07 | Biotron Ltd | Acylguanidine compounds with antiviral activity |
US8067391B2 (en) | 2005-10-03 | 2011-11-29 | University Health Network | ODCase inhibitors for the treatment of malaria |
WO2007056170A2 (fr) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Derives pyrrolo-[2,1-f]-[1,2,4]-triazin-4-ylamines inhibiteurs de la igf-1r kinase pour le traitement des cancers et autres maladies hyperproliferatives |
CN101321522B (zh) | 2005-12-01 | 2012-05-30 | 巴斯利尔药物股份公司 | 环氧丁醇中间体的制备方法 |
PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
CN101466710B (zh) | 2005-12-02 | 2013-05-29 | 拜尔健康护理有限责任公司 | 用于治疗与血管生成有关的过度增殖性病症和疾病的取代的4-氨基-吡咯并三嗪衍生物 |
RU2422454C2 (ru) | 2005-12-09 | 2011-06-27 | Ф. Хоффманн-Ля Рош Аг | Антивирусные нуклеозиды |
WO2007065289A2 (fr) | 2005-12-09 | 2007-06-14 | Basilea Pharmaceutica Ag | 4-oxo-(iso)tretinoine pour le traitement topique des troubles dermatologiques severes |
CA2637879A1 (fr) | 2006-02-14 | 2007-08-23 | Merck & Co., Inc. | Phosphoramidates d'aryle nucleosidiques pour le traitement d'infections ribovirales dependantes de l'arn |
WO2007097991A2 (fr) | 2006-02-16 | 2007-08-30 | Pharmasset, Inc. | Méthodes et trousses pour administrer des agents antiviraux |
DE102006015378A1 (de) | 2006-04-03 | 2007-10-04 | Ludwig-Maximilians-Universität München | Verfahren zur Synthese von Organoelementverbindungen |
AR061024A1 (es) | 2006-05-22 | 2008-07-30 | Novartis Ag | Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona. |
US7842672B2 (en) | 2006-07-07 | 2010-11-30 | Gilead Sciences, Inc. | Phosphonate inhibitors of HCV |
WO2008033466A2 (fr) | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions et procédés pour le traitement de maladies virales |
EP2079753A1 (fr) | 2006-11-06 | 2009-07-22 | Boehringer Ingelheim International GmbH | Dérivés de benzyl-benzonitrile substitués par glucopyranosyle, médicaments contenant de tels composés, leur utilisation et procédé pour leur fabrication |
WO2008079206A1 (fr) | 2006-12-20 | 2008-07-03 | Merck & Co., Inc. | Phosphoramidates cycliques nucléosidiques pour le traitement d'infections virales arn dépendantes |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
JP2010515680A (ja) | 2007-01-05 | 2010-05-13 | メルク・シャープ・エンド・ドーム・コーポレイション | Rna依存性rnaウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート |
US8440813B2 (en) | 2007-01-12 | 2013-05-14 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
EP2125819B1 (fr) | 2007-03-21 | 2014-10-22 | Bristol-Myers Squibb Company | Composés hétérocycliques fusionnés utiles pour le traitement de maladies prolifératives, allergiques, auto-immunes ou inflammatoires |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
WO2008141079A1 (fr) | 2007-05-10 | 2008-11-20 | Biocryst Pharmaceuticals, Inc. | Composés de tétrahydrofuro [3,4-d] dioxolane pour utilisation dans le traitement d'infections virales et de cancer |
CN100532388C (zh) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
AU2008286240B2 (en) | 2007-08-03 | 2013-05-23 | Biotron Limited | Hepatitis C antiviral compositions and methods |
KR101502533B1 (ko) | 2007-11-22 | 2015-03-13 | 에스케이케미칼주식회사 | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 |
TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
US8227431B2 (en) | 2008-03-17 | 2012-07-24 | Hetero Drugs Limited | Nucleoside derivatives |
BRPI0911410A2 (pt) | 2008-04-23 | 2015-10-06 | Gilead Sciences Inc | análogos de carba-nucleosídeo para tratamento antiviral |
US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
WO2010036407A2 (fr) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Analogues nucléosidiques antiviraux |
EP2313102A2 (fr) * | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Nucléosides bicycliques et nucléotides convenant comme agents thérapeutiques |
PE20160858A1 (es) | 2009-02-10 | 2016-09-03 | Gilead Sciences Inc | Analogos carba-nucleosidicos para tratamiento antiviral |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
EP2408306A4 (fr) | 2009-03-20 | 2012-11-07 | Alios Biopharma Inc | Nucleoside substitue et analogues nucleotidiques |
CA2755950C (fr) | 2009-03-24 | 2017-04-25 | Biocryst Pharmaceuticals, Inc. | Sels pharmaceutiques utiles de 7-[(3r,4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
MX2012000959A (es) | 2009-07-21 | 2012-03-06 | Gilead Sciences Inc | Inhibidores de los virus flaviviridae. |
SI2480559T1 (sl) | 2009-09-21 | 2013-10-30 | Gilead Sciences, Inc. | Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov |
US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
PE20210668A1 (es) | 2009-09-21 | 2021-04-05 | Gilead Sciences Inc | Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales |
US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
KR101467858B1 (ko) | 2009-12-28 | 2014-12-02 | 재단법인 생물기술개발중심 | mTOR 및 PI3K 억제제로서의 신규 피리미딘 화합물 |
EP2752422B1 (fr) | 2010-03-31 | 2017-08-16 | Gilead Pharmasset LLC | Synthèse stéréosélective d'agents actifs contenant du phosphore |
WO2011123672A1 (fr) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Phosphoramidate de nucléoside de type purine |
TW201201815A (en) * | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
KR20200052384A (ko) | 2010-07-19 | 2020-05-14 | 길리애드 사이언시즈, 인코포레이티드 | 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법 |
PT2595980E (pt) * | 2010-07-22 | 2014-11-27 | Gilead Sciences Inc | Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae |
TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之2’-氟取代之碳-核苷類似物 |
BR112013008017A2 (pt) | 2010-09-20 | 2016-06-14 | Gilead Sciences Inc | análogos de carba-nucleosídeo 2-flúor substituídos para tratamento antiviral |
NZ607996A (en) * | 2010-09-22 | 2014-07-25 | Alios Biopharma Inc | Substituted nucleotide analogs |
BR112013009029B1 (pt) | 2010-10-15 | 2021-06-29 | Biocryst Pharmaceuticals, Inc. | Métodos e composições para inibição de polimerase |
ES2716158T3 (es) | 2010-11-30 | 2019-06-10 | Gilead Pharmasset Llc | 2'-spiro-nucleótidos para el tratamiento de hepatitis C |
CA2822037A1 (fr) | 2010-12-20 | 2012-06-28 | Gilead Sciences, Inc. | Combinations pour traiter le vhc |
EA201391264A1 (ru) | 2011-04-13 | 2014-03-31 | Джилид Сайэнс, Инк. | 1'-замещенные пиримидиновые n-нуклеозидные аналоги для противовирусного лечения |
JP2014515023A (ja) | 2011-04-13 | 2014-06-26 | メルク・シャープ・アンド・ドーム・コーポレーション | 2’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法 |
ES2639122T3 (es) | 2011-05-13 | 2017-10-25 | Zoetis Services Llc | Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah |
MD4589C1 (ro) * | 2011-09-16 | 2019-03-31 | Gilead Pharmasset Llc | Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US20130143835A1 (en) | 2011-12-05 | 2013-06-06 | Medivir Ab | HCV Polymerase Inhibitors |
WO2013084165A1 (fr) | 2011-12-05 | 2013-06-13 | Medivir Ab | Inhibiteurs de vhc polymérase |
EP2794630A4 (fr) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | Analogues de nucléotide phosphorothioate substitués |
NZ702744A (en) | 2012-05-22 | 2016-12-23 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
EP2890704B1 (fr) | 2012-08-31 | 2018-02-28 | Novartis AG | Dérivés de 2'-éthynyle nucléoside de traitement d'infections virales |
KR20150054795A (ko) | 2012-09-10 | 2015-05-20 | 에프. 호프만-라 로슈 아게 | B형 간염 바이러스 감염의 치료 및 예방을 위한 6-아미노산 헤테로아릴다이하이드로피리미딘 |
WO2014042433A2 (fr) | 2012-09-14 | 2014-03-20 | Kainos Medicine, Inc. | Composés et compositions de modulation de l'activité du récepteur adénosine a3 |
CA2890905A1 (fr) * | 2012-11-16 | 2014-05-22 | Biocryst Pharmaceuticals, Inc. | Nucleosides antiviraux contenant de l'azasucre |
JP2016501200A (ja) | 2012-11-19 | 2016-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | ウイルス性疾患を処置するための2−アルキニル置換ヌクレオシド誘導体 |
KR102168621B1 (ko) | 2012-12-21 | 2020-10-22 | 얀센 바이오파마, 인코퍼레이트. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체 |
US9283242B2 (en) * | 2013-01-22 | 2016-03-15 | Massachusetts Institute Of Technology | Uses of dihydro bases |
US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
US20140309164A1 (en) | 2013-04-12 | 2014-10-16 | Achillion Pharmaceuticals, Inc. | Deuterated nucleoside prodrugs useful for treating hcv |
US9542154B2 (en) | 2013-06-25 | 2017-01-10 | Intel Corporation | Fused multiply add operations using bit masks |
UA117375C2 (uk) | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
RS61540B1 (sr) | 2013-09-11 | 2021-04-29 | Inst Nat Sante Rech Med | Postupci i farmaceutske kompozicije za tretiranje infekcije hepatitis b virusa |
UA119050C2 (uk) | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
EA201691261A1 (ru) | 2014-01-30 | 2016-11-30 | Ф. Хоффманн-Ля Рош Аг | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b |
PT3114128T (pt) | 2014-03-07 | 2019-02-27 | Hoffmann La Roche | Novas heteroarildihidropirimidinas fundidas em 6 para o tratamento e profilaxia da infeção pelo vírus da hepatite b. |
WO2015173164A1 (fr) | 2014-05-13 | 2015-11-19 | F. Hoffmann-La Roche Ag | Nouvelles dihydroquinolizinones pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b |
US9504701B2 (en) | 2014-06-02 | 2016-11-29 | The Board Of Regents Of The University Of Texas System | Methods for treating viral infections using hydrogen sulfide donors |
US9616076B2 (en) | 2014-06-02 | 2017-04-11 | The Board Of Regents Of The University Of Texas Systems | Methods for treating viral infections using hydrogen sulfide donors |
WO2016012470A1 (fr) | 2014-07-25 | 2016-01-28 | F. Hoffmann-La Roche Ag | Nouvelles formes amorphes et cristallines de l'acide (3s)-4-[[(4r)-4-(2-chloro-4-fluorophényl)-5-méthoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]méthyl]morpholine-3-carboxilique |
CA2952541C (fr) | 2014-08-14 | 2019-10-01 | F. Hoffmann-La Roche Ag | Pyridazones et triazinones pour le traitement et la prevention de l'infection par le virus de l'hepatite b |
TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
US9637485B2 (en) | 2014-11-03 | 2017-05-02 | Hoffmann-La Roche Inc. | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection |
US9676793B2 (en) | 2014-12-23 | 2017-06-13 | Hoffmann-Laroche Inc. | Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same |
WO2016102438A1 (fr) | 2014-12-23 | 2016-06-30 | F. Hoffmann-La Roche Ag | Procédé de préparation d'analogues de 4-phényl-5-alcoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine |
WO2016107832A1 (fr) | 2014-12-30 | 2016-07-07 | F. Hoffmann-La Roche Ag | Nouvelles tétrahydropyridopyrimidines et tétrahydropyridopyridines pour le traitement et la prévention d'une infection par le virus de l'hépatite b |
WO2016107833A1 (fr) | 2014-12-31 | 2016-07-07 | F. Hoffmann-La Roche Ag | Nouveau procédé à haut débit pour la quantification d'adnccc du virus de l'hépatite b (hbv) à partir de lysat cellulaire par pcr en temps réel |
MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
EP3250685A1 (fr) | 2015-01-27 | 2017-12-06 | F. Hoffmann-La Roche AG | Adnccc du virus de l'hépatite b (hbv) recombiné, procédé pour générer ce dernier et utilisation associée |
CN107207505B (zh) | 2015-02-11 | 2018-12-14 | 豪夫迈·罗氏有限公司 | 治疗和预防乙型肝炎病毒感染的 2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物 |
CA2998189C (fr) * | 2015-09-16 | 2021-08-03 | Gilead Sciences, Inc. | Procedes pour le traitement d'infections virales a arenaviridae et coronaviridae |
WO2017184668A1 (fr) | 2016-04-20 | 2017-10-26 | Gilead Sciences, Inc. | Méthodes de traitement d'infections virales à flaviviridae |
CN108299532B (zh) | 2016-12-29 | 2020-12-22 | 广东东阳光药业有限公司 | 一种抗病毒核苷类似物前药及其组合物、用途 |
BR112019016316A2 (pt) | 2017-02-08 | 2020-03-31 | Biotron Limited | Métodos para o tratamento da influenza |
CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
CN115403626A (zh) | 2017-05-01 | 2022-11-29 | 吉利德科学公司 | 新结晶形式 |
US10675296B2 (en) | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
CN111265532A (zh) | 2020-01-21 | 2020-06-12 | 中国人民解放军军事科学院军事医学研究院 | 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用 |
WO2021154687A1 (fr) | 2020-01-27 | 2021-08-05 | Gilead Sciences, Inc. | Procédés de traitement d'infections par sras cov-2 |
CN115298181A (zh) | 2020-03-12 | 2022-11-04 | 吉利德科学公司 | 制备1’-氰基核苷的方法 |
EP4132651A1 (fr) | 2020-04-06 | 2023-02-15 | Gilead Sciences, Inc. | Formulations d'inhalation d'analogues de carbanucléosides à substitution 1'-cyano |
CA3179226A1 (fr) * | 2020-05-29 | 2021-12-02 | Tomas Cihlar | Methodes de traitement par remdesivir |
PE20231983A1 (es) | 2020-08-27 | 2023-12-12 | Gilead Sciences Inc | Compuestos y metodos para el tratamiento de infecciones virales |
-
2016
- 2016-09-16 CA CA2998189A patent/CA2998189C/fr active Active
- 2016-09-16 MX MX2021005087A patent/MX2021005087A/es unknown
- 2016-09-16 AU AU2016323604A patent/AU2016323604B2/en active Active
- 2016-09-16 SG SG10202109869X patent/SG10202109869XA/en unknown
- 2016-09-16 BR BR122020020217-3A patent/BR122020020217B1/pt active IP Right Grant
- 2016-09-16 EP EP20201732.3A patent/EP3785717B1/fr active Active
- 2016-09-16 MA MA042819A patent/MA42819A/fr unknown
- 2016-09-16 PT PT202017323T patent/PT3785717T/pt unknown
- 2016-09-16 CN CN202211260104.7A patent/CN115844896A/zh active Pending
- 2016-09-16 HU HUE20201732A patent/HUE057928T2/hu unknown
- 2016-09-16 HR HRP20220355TT patent/HRP20220355T1/hr unknown
- 2016-09-16 CN CN202310794837.7A patent/CN116617233A/zh active Pending
- 2016-09-16 KR KR1020187010186A patent/KR20180050742A/ko not_active Application Discontinuation
- 2016-09-16 EP EP16770866.8A patent/EP3349758B1/fr active Active
- 2016-09-16 MX MX2018003161A patent/MX2018003161A/es unknown
- 2016-09-16 HU HUE16770866A patent/HUE058737T2/hu unknown
- 2016-09-16 MA MA052371A patent/MA52371A/fr unknown
- 2016-09-16 EA EA201890494A patent/EA038141B1/ru unknown
- 2016-09-16 PL PL16770866.8T patent/PL3349758T3/pl unknown
- 2016-09-16 DK DK20201732.3T patent/DK3785717T3/da active
- 2016-09-16 BR BR112018005048A patent/BR112018005048B8/pt active IP Right Grant
- 2016-09-16 JP JP2018513840A patent/JP6742403B2/ja active Active
- 2016-09-16 HR HRP20220740TT patent/HRP20220740T1/hr unknown
- 2016-09-16 PT PT167708668T patent/PT3349758T/pt unknown
- 2016-09-16 PL PL20201732T patent/PL3785717T3/pl unknown
- 2016-09-16 WO PCT/US2016/052092 patent/WO2017049060A1/fr active Application Filing
- 2016-09-16 LT LTEPPCT/US2016/052092T patent/LT3349758T/lt unknown
- 2016-09-16 SG SG10202001878WA patent/SG10202001878WA/en unknown
- 2016-09-16 ES ES20201732T patent/ES2909419T3/es active Active
- 2016-09-16 LT LTEP20201732.3T patent/LT3785717T/lt unknown
- 2016-09-16 CN CN202210173558.4A patent/CN114366745A/zh active Pending
- 2016-09-16 SI SI201631491T patent/SI3785717T1/sl unknown
- 2016-09-16 EP EP22166415.4A patent/EP4088718A1/fr active Pending
- 2016-09-16 CN CN202211259911.7A patent/CN115887465A/zh active Pending
- 2016-09-16 ES ES16770866T patent/ES2918585T3/es active Active
- 2016-09-16 SI SI201631548T patent/SI3349758T1/sl unknown
- 2016-09-16 CN CN201680066796.8A patent/CN108348526A/zh active Pending
- 2016-09-16 US US15/267,433 patent/US10251904B2/en active Active
- 2016-09-16 DK DK16770866.8T patent/DK3349758T3/da active
- 2016-09-19 TW TW105130244A patent/TW201733595A/zh unknown
-
2018
- 2018-11-21 HK HK18114885.9A patent/HK1255732A1/zh unknown
- 2018-12-12 HK HK18115972.0A patent/HK1256872A1/zh unknown
- 2018-12-31 HK HK18116756.0A patent/HK1257628A1/zh unknown
-
2019
- 2019-02-01 US US16/265,016 patent/US10695361B2/en active Active
-
2020
- 2020-03-16 JP JP2020045662A patent/JP7254738B2/ja active Active
- 2020-04-30 US US16/863,566 patent/US11007208B2/en active Active
- 2020-09-17 AU AU2020233714A patent/AU2020233714B2/en active Active
-
2021
- 2021-04-05 US US17/222,066 patent/US11382926B2/en active Active
- 2021-04-15 JP JP2021069068A patent/JP2021107431A/ja not_active Withdrawn
-
2022
- 2022-03-22 CY CY20221100231T patent/CY1125089T1/el unknown
- 2022-05-19 US US17/748,400 patent/US20230027727A1/en not_active Abandoned
-
2023
- 2023-02-20 AU AU2023200990A patent/AU2023200990A1/en active Pending
- 2023-04-05 JP JP2023061379A patent/JP2023085459A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42819A (fr) | Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae | |
MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
MA45192A (fr) | Traitement d'association | |
MA40867A (fr) | Méthodes pour le traitement d'infections virales à filoviridae | |
MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA46427A (fr) | Compositions d'oligonucléotides et procédés associés | |
MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
MA49069A (fr) | Procédés et compositions pour le traitement d'apnée du sommeil | |
MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA42439A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
ITUA20164498A1 (it) | Metodo ed apparato per l'impiego di droni in applicazioni antincendio | |
MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA46836A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
MA53558A (fr) | Compositions et procédés pour le traitement d'infections virales | |
MA45270A (fr) | Compositions d'oligonucléotides et procédés associés | |
MA46791A (fr) | Composés et procédés pour réduire l'expression d'atxn3 | |
MA50849A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
MA51306A (fr) | Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
FR3032353B1 (fr) | Composition pharmaceutique et dispositif pour le traitement de la douleur |